Assoc. Prof. Emma Hamilton-Williams

PhD, BSc

A/Prof Emma Hamilton-Williams’ laboratory currently focuses on developing an immunotherapy for type 1 diabetes as well as understanding the role of the gut microbiota in as a potential trigger for type 1 diabetes. Her laboratory is using nanoparticle technology to deliver an immunotherapy that specifically tolerises the immune cells that cause type 1 diabetes and is working towards a first-in -human trial of this approach. She uses state-of-the-art protein sequencing techniques to probe how disturbances in the gut microbiota of children with type 1 diabetes impacts the function of the gut and the pancreas. She recently currently conducted a clinical trial of a microbiome-targeting dietary supplement aimed at restoring a healthy microbiome and immune tolerance with an ultimate aim of preventing type 1 diabetes.


Articles by this Author